← Back to All US Stocks

CBD Life Sciences Inc. (CBDL) Fundamental Analysis & AI Grade 2026

CBDL OTC Medicinal Chemicals & Botanical Products NV CIK: 0001776073
Recently Updated • Analysis: Jul 12, 2026 • SEC Data: 2026-07-12

CBD Life Sciences Inc. (CBDL) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CBDL Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

CBDL vs Materials Sector: How CBD Life Sciences Inc. Compares

How CBD Life Sciences Inc. compares to Materials sector averages

Net Margin
CBDL 0.0%
vs
Sector Avg 10.0%
CBDL Sector
ROE
CBDL 0.0%
vs
Sector Avg 14.0%
CBDL Sector
Current Ratio
CBDL 0.0x
vs
Sector Avg 1.6x
CBDL Sector
Debt/Equity
CBDL 0.0x
vs
Sector Avg 0.6x
CBDL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is CBD Life Sciences Inc. Stock Overvalued? CBDL Valuation Analysis 2026

Based on fundamental analysis, CBD Life Sciences Inc. has mixed fundamental signals relative to the Materials sector in 2026.

Return on Equity
N/A
Sector avg: 14%
Net Profit Margin
N/A
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

CBD Life Sciences Inc. Balance Sheet: CBDL Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

CBDL Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

CBDL SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for CBD Life Sciences Inc. (CIK: 0001776073)

Frequently Asked Questions about CBDL

What is the AI rating for CBDL?

CBD Life Sciences Inc. (CBDL) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CBDL's key strengths?

Claude: Analysis in progress.

What are the risks of investing in CBDL?

Claude: Analysis in progress.

What is CBDL's revenue and growth?

CBD Life Sciences Inc. reported revenue of N/A.

Does CBDL pay dividends?

CBD Life Sciences Inc. does not currently pay dividends.

Where can I find CBDL SEC filings?

Official SEC filings for CBD Life Sciences Inc. (CIK: 0001776073) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CBDL's EPS?

CBD Life Sciences Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is CBDL's fundamental grade?

Based on our AI fundamental analysis in July 2026, CBD Life Sciences Inc. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is CBDL stock overvalued or undervalued?

Valuation metrics for CBDL: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

What is CBDL's AI grade for 2026?

Our dual AI analysis gives CBD Life Sciences Inc. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is CBDL's free cash flow?

CBD Life Sciences Inc.'s operating cash flow is N/A, with capital expenditures of N/A.

How does CBDL compare to other Materials stocks?

Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% CRDO 87% AVGO 87%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Jul 12, 2026 | Data as of: 2026-07-12 | Powered by Claude AI